Carbohydrate blocker clinical study overview
"Phase 2" is the name of a derivative that is used as a main ingredient in Dietrine. It has shown to effectively block the body from absorbing the calories derived from carbohydrates.
Below are two significant clinical studies that prove that Dietrine is effective at blocking carbohydrate derived calories and that it can help in weight loss and slimming goals
Clinical Study 1: SUCCESS
In vivo effectiveness of a starch absorption blocker in a double-blind placebo-controlled study with normal college-age subjects.
Joe A. Vinson, PhD and Donna M. Shuta, BS
Department of Chemistry
University of Scranton
Scranton, PA 18510
Inhibition of carbohydrate metabolism or absorption is one mechanism to reduce hyperglycemia in normal and especially in diabetic subjects. Another possible benefit is the decrease in calorie intake after eating carbohydrates for obesity and weight loss.
In the 1980's there were several reports of in vitro and in vivo effectiveness of a natural starch blocker that worked by inactivating the enzyme amylase. We investigated this hypothesis with an initial pilot study. After this initial study with subjects who were physically active during the study, we did a second study to confirm the results.
In this second study, again there was a double-blind placebo-controlled crossover trial with ten subjects (five males and five females aged 21 to 27) who participated with informed consent. After an overnight fast the subjects appeared in the morning and were given in a random fashion either 1) placebo consisting of 4 slices of white bread (60 g of carbohydrate), 42 g of soybean oil margarine, and 4 g of Sweet N'Low; 2) experimental comprising the control plus 1.5 g of Phase 2 (the main ingredient of Dietrine). The subjects rested between blood drawings.
As expected the control bread produced an increase in glucose in the normal subjects that reached a broad peak after 45 minutes. The peak glucose for the Phase 2 group occurred at 30 minutes. This dose of Phase 2 produced a smaller increase than the control from 15 to 80 minutes, with an almost significant difference (p < 0.1) at 45 and 60 minutes.
These results show the effectiveness of the product in decreasing the absorption of glucose from complex carbohydrates from this group of subjects.
Clinical Study 2: SUCCESS.
Investigation of the efficacy of Phase 2 , a purified bean extract from Pharmachem Laboratories
Joe A. Vinson, Ph.D.
Department of Chemistry
University of Scranton
Amylase is a digestive tract enzyme, which breaks down starch into small units capable of being further degraded to glucose, which is used for fuel for normal metabolism and body homeostasis. Clinical use of inhibitors of amylase activity has widespread appeal because a controlled reduction of starch digestion could influence carbohydrate uptake in diabetes and obesity, the latter of which is a current problem with 20% of the US population.
Five males and five females (ages 21 to 57) participated in a double-blind placebo controlled crossover study with informed consent. All subjects were employees at a commercial clinical laboratory and went about their duties as secretaries and technicians during the study.
After an overnight fast, the participants were sampled for blood and then given in a random manner either 1) placebo consisting of 4 slices of white bread (60 grams of carbohydrate), 42 grams of soybean oil margarine and 4 grams of Sweet N'Low spread on the bread; 2) experimental comprising the placebo plus 1.5 grams of Phase 2 prepared by Pharmachem Laboratories. Plasma glucose wasmeasured, by a commercial enzyme kit (Sigma Chemical Company), from blood drawn at baseline every 30 minutes for 4 hours. After 1 week the regimen was repeated with the other supplement.
The subjects were normoglycemic as measured by fasting glucose concentration, which averaged 98 mg/dl for the placebo and 104 for the Phase 2 . From 60 to 120 minutes (as seen in the accompanying figure) the change in plasma glucose of the Phaseolamin group from the baseline was 1/3 of the level of the placebo group. Phaseolamin consumption caused the plasma glucose to return to baseline values 20 minutes earlier than the placebo without Phaseolamin.
The average area under the plasma glucose-time curve from 0 to 150 minutes, which is a measure of absorption and metabolism, was 57% lower with Phaseolamin. Plotting the average change in glucose concentration from 30 minutes to 210 minutes, the area under the curve was positive for the placebo but negative for Phase 2 .
This indicates that very little of the glucose from the starch in the bread was absorbed when co-ingested with Phase 2 and the glucose was cleared very rapidly. No side effects were observed with this product.
(Source: http://www.dietrine.com)
